Reconsidering First-Line Therapy for Clarithromycin-Resistant Helicobacter pylori in Korea: The Role of Bismuth-Augmented Triple Therapy | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled TrialCohort Study · 2026
2Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 GuidelineReview · 2026 · 3 citations
3Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trialRetrospective Study · 2019 · 30 citations
4Prospective Randomised Study of a 14 day Clarithromycin Triple Regimen and a 14 Day Bismuth based Quadruple Regimen for Helicobacter Pylori Eradication2025
5Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised EditionMeta-Analysis · 2026 · 1 citations

More from Gut and Liver

More from Yonsei University